Comment by
lscfa on Feb 26, 2022 11:21am
Normally co.s disclose if the target acquisition has revenues and ebitda so shareholders can determine if co. is overpaying. ScreenPro made us think it was buying a pre-revenue co.
Comment by
WalkingDead01 on Feb 28, 2022 2:40am
From CEO.CA : Add Biomedical is a subsidiary of another company in Korea. They will have the ability to expand on other testing. Using the current labs and staff, they are in for the long term expansion in Canada. https://www.addbiomeditek.com/